113 related articles for article (PubMed ID: 17160557)
1. Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?
Tankó LB; Karsdal MA; Christiansen C; Leeming DJ
Cancer Metastasis Rev; 2006 Dec; 25(4):659-68. PubMed ID: 17160557
[TBL] [Abstract][Full Text] [Related]
2. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
[TBL] [Abstract][Full Text] [Related]
4. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
Clemons M; Dranitsaris G; Cole D; Gainford MC
Oncologist; 2006 Mar; 11(3):227-33. PubMed ID: 16549806
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of metastatic bone disease and risk of skeletal morbidity.
Coleman RE
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6243s-6249s. PubMed ID: 17062708
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of markers of bone turnover in metastatic bone disease.
Seibel MJ
Nat Clin Pract Oncol; 2005 Oct; 2(10):504-17; quiz 1 p following 533. PubMed ID: 16205770
[TBL] [Abstract][Full Text] [Related]
7. Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem.
Pluijm G; Löwik C; Papapoulos S
Cancer Treat Rev; 2000 Feb; 26(1):11-27. PubMed ID: 10660489
[TBL] [Abstract][Full Text] [Related]
8. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
Saad F; Lipton A
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
[TBL] [Abstract][Full Text] [Related]
10. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer.
Kosteva J; Langer C
Curr Opin Oncol; 2008 Mar; 20(2):155-61. PubMed ID: 18300765
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of markers of bone degradation and formation.
Demers LM
Scand J Clin Lab Invest Suppl; 1997; 227():12-20. PubMed ID: 9127464
[TBL] [Abstract][Full Text] [Related]
13. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
14. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
Leeming DJ; Delling G; Koizumi M; Henriksen K; Karsdal MA; Li B; Qvist P; Tankó LB; Byrjalsen I
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1392-5. PubMed ID: 16835341
[TBL] [Abstract][Full Text] [Related]
15. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
16. Bone markers in the management of metastatic bone disease.
Lipton A; Costa L; Ali SM; Demers LM
Cancer Treat Rev; 2001 Jun; 27(3):181-5. PubMed ID: 11417969
[TBL] [Abstract][Full Text] [Related]
17. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
Russell MR; Jamieson WL; Dolloff NG; Fatatis A
Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
[TBL] [Abstract][Full Text] [Related]
18. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).
Ye L; Kynaston HG; Jiang WG
Int J Mol Med; 2007 Jul; 20(1):103-11. PubMed ID: 17549396
[TBL] [Abstract][Full Text] [Related]
19. The use of molecular markers of bone turnover in the management of patients with metastatic bone disease.
Seibel MJ
Clin Endocrinol (Oxf); 2008 Jun; 68(6):839-49. PubMed ID: 17980010
[TBL] [Abstract][Full Text] [Related]
20. Skeletal implications of prostate cancer.
Bagi CM
J Musculoskelet Neuronal Interact; 2003 Jun; 3(2):112-7. PubMed ID: 15758351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
